Consequently, molecular docking with naringenin was performed using AKT1, TP53, SRC, MAPK1, MAPK3, and HSP90AA1 as the hub targets for naringenin to cure COVID-19/LUSC. The gene discussed is TP53; the disease is COVID-19.